Radioimmunodetection of lung cancer with IMACIS-1, I-131 labeled monoclonal antibodies to CEA and CA19-9
IMACIS-1 is a radiopharmaceutical containing a mixture of Iodine-131 labeled monoclonal antibodies to CEA and CA19-9. IMACIS-1 immunoscintigraphy was evaluated for tumor detection in 7 primary lung cancer and 2 metastatic lung cancer patients who received radiotherapy. No adverse side effects due to IMACIS-1 were observed in this study. Positive detection was achieved in 5 of 9 patients (55.6%). It was less, but nearly the same as the detection rate obtained with Gallium-67 citrate (67Ga-citrate) in these patients. There was no clear correlation between IMACIS-1 accumulation and the CEA or CA19-9 serum levels. The IMACIS-1 positive detection rate decreased in many of the irradiated lesions. We considered that the decreased number of tumor cells and changes in blood perfusion are some of the factors controlling accumulation in tumors.
Key wordsimmunoscintigraphy IMACIS-1 lung cancer radiotherapy Ga-67 citrate
Unable to display preview. Download preview PDF.
- 1.Sasaki Y, Inoue T, Mitsuhashi N, et al: Clinical evaluation of immunoscintigraphy with I-131 anti-CEA and I-131 anti-CA19-9 monoclonal antibody cocktail (IMACIS-1)—Report of phase II study—.Jpn J Nucl Med 27: 349–362, 1990Google Scholar
- 3.Robert EH, Robert EP, James LQ III: Scanning treated Hodgkin’s disease with Ga-67 citrate.Radiology 110: 151–154, 1974Google Scholar
- 4.Takahashi T, Tsujino D, Kato Y, et al: Clinical evaluation of immunoscintigraphy using IMACIS-1.J Jpn Soc Cancer Ther 24: 169, 1989Google Scholar
- 8.Mitsuhashi N, Yamakawa M, Kazumoto T, et al: Experimental studies on changes of tumor antigenicity by irradiationin vitro.J Jpn Soc Ther Radiol Oncol 1 (Supplement 1): 13, 1989Google Scholar
- 9.Mitsuhashi N, Takahashi M, Okazaki A, et al: Interactions of radiation and Biological Response Modifiers (BRMs) in the treatment of malignant tumor.Jpn J Cancer Clin 36 (13): 2272–2277, 1990Google Scholar
- 11.Mitsuhashi N, Kazumoto T, Nakayama Y, et al: Experimental study of tumor detection using I-131 labeled F (ab’)2 fragments of monoclonal antibodies to CA19-9 and CEA (IMACIS-1).Jpn J Cancer Clin 35 (15): 1753–1758, 1989Google Scholar
- 13.Sugiyama S, Furuta M, Suzuki Y, et al: Clinical evaluation of immunoscintigraphy using a cocktail of I-131 labeled anti-CEA and anti-CA19-9 monoclonal antibodies.Image technology & information display 20: 1101–1107, 1988Google Scholar
- 14.Mitsuhashi N, Niibe H, Yamakawa M, et al: The clinical evaluation of serum CA19-9 and CA12-5 levels in patients with malignant tumors—Comparison with serum CEA levels—.Jpn J Nucl Med 22 (12): 1835–1841, 1985Google Scholar